ImmunityBio Receives United Arab Emirates (UAE) Marketing Authorization for ANKTIVA® Across BCG-Unresponsive Non-Muscle Invasive Bladder Cancer for CIS and Papillary Disease and Metastatic Non-Small

Go back to ImmunityBio Receives United Arab Emirates (UAE) Marketing Authorization for ANKTIVA® Across BCG-Unresponsive Non-Muscle Invasive Bladder Cancer for CIS and Papillary Disease and Metastatic Non-Small
(NASDAQ: IBRX) Delayed: 8.48 +0.02 (0.24%)
Previous Close $8.46    52 Week High
Open $8.46    52 Week Low
Day High $8.53    P/E N/A 
Day Low $8.20    EPS
Volume 18,439,099